[go: up one dir, main page]

AR091039A1 - Composiciones farmaceuticas topicas que comprenden terbinafina, uso y metodo de tratamiento - Google Patents

Composiciones farmaceuticas topicas que comprenden terbinafina, uso y metodo de tratamiento

Info

Publication number
AR091039A1
AR091039A1 ARP130101657A AR091039A1 AR 091039 A1 AR091039 A1 AR 091039A1 AR P130101657 A ARP130101657 A AR P130101657A AR 091039 A1 AR091039 A1 AR 091039A1
Authority
AR
Argentina
Prior art keywords
weight
pharmaceutical compositions
treatment method
terbinafine
include terbinafine
Prior art date
Application number
Other languages
English (en)
Inventor
Willers Christoph
Fielhauser Sabine
Gorissen Sascha
Evers Dirk
Heinrich-Herbig Michael
Mallwitz Henning
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46148606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR091039(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of AR091039A1 publication Critical patent/AR091039A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica tópica caracterizada porque comprende, en base al peso total de la composición: a) entre 1,5% en peso y 5% en peso de terbinafina o cualquier sal farmacéuticamente aceptable de la misma; b) entre 15% en peso y 35% en peso de urea; y c) más que 25% en peso de agua. Reivindicación 19: El uso de acuerdo con la reivindicación 18 caracterizado porque el agente antifúngico se selecciona entre terbinafina, amorolfina y ciclopirox, o cualquier sal farmacéuticamente aceptable de los mismos.
ARP130101657 2012-05-14 2013-05-14 Composiciones farmaceuticas topicas que comprenden terbinafina, uso y metodo de tratamiento AR091039A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20120003791 EP2664327A1 (en) 2012-05-14 2012-05-14 Topical pharmaceutical compositions comprising terbinafide and urea

Publications (1)

Publication Number Publication Date
AR091039A1 true AR091039A1 (es) 2014-12-30

Family

ID=46148606

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101657 AR091039A1 (es) 2012-05-14 2013-05-14 Composiciones farmaceuticas topicas que comprenden terbinafina, uso y metodo de tratamiento

Country Status (20)

Country Link
US (1) US20150111971A1 (es)
EP (2) EP2664327A1 (es)
JP (1) JP2015516455A (es)
KR (1) KR20150013162A (es)
CN (1) CN104302281A (es)
AR (1) AR091039A1 (es)
AU (1) AU2013261918A1 (es)
BR (1) BR112014028280A2 (es)
CA (1) CA2872210A1 (es)
CL (1) CL2014003081A1 (es)
CO (1) CO7131352A2 (es)
EA (1) EA201492091A1 (es)
HK (1) HK1202808A1 (es)
IL (1) IL235241A0 (es)
MX (1) MX2014013851A (es)
PH (1) PH12014502512A1 (es)
SG (1) SG11201407536UA (es)
TW (1) TW201350107A (es)
WO (1) WO2013171159A1 (es)
ZA (1) ZA201407655B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201317005D0 (en) * 2013-09-25 2013-11-06 Blueberry Therapeutics Ltd Composition and methods of treatment
DK3209319T3 (da) 2014-10-21 2021-10-04 Hexima Ltd En fremgangsmåde til behandling af svampeinfektioner
GB201605127D0 (en) * 2016-03-25 2016-05-11 Blueberry Therapeutics Ltd Composition and methods of treatment
AU2018221880B2 (en) * 2017-02-15 2023-08-17 Botanix Pharmaceuticals Ltd Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases
EP3492068A1 (en) * 2017-12-01 2019-06-05 NCP NewCare Products GmbH Composition for treating onychomycosis
WO2019214838A1 (en) * 2018-05-09 2019-11-14 Eviderm Institute Ab Use of an alcohol-containing composition for improving the skin barrier function
PL245223B1 (pl) * 2019-01-10 2024-06-03 Biotts Spolka Akcyjna Nośnik farmaceutyczny dla substancji czynnych oraz kompozycja farmaceutyczna go zawierająca
JP6591100B1 (ja) * 2019-01-25 2019-10-16 ロート製薬株式会社 爪及び爪周り用医薬組成物
CA3264916A1 (en) * 2022-08-17 2024-02-22 Lyotropic Delivery Systems Ltd. Topical administration of antifungal agents for the treatment of fungal infections
KR102597564B1 (ko) * 2023-03-03 2023-11-03 장병모 조갑 및 피부 백선의 예방 또는 치료용 약학적 조성물
EP4470526A3 (en) 2023-07-25 2025-01-15 MiM Pharma GmbH Topical composition for administration to nails

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281239B1 (en) * 2000-04-12 2001-08-28 Bradley Pharmeaceuticals, Inc. Method of treating onychomycosis
WO2011014850A2 (en) * 2009-07-31 2011-02-03 Nuvo Research Inc. Topical eutectic-based formulations
EP2544659A2 (en) * 2009-12-23 2013-01-16 Nuvo Research Inc. Highly permeating terbinafine formulation for treating onychomycosis

Also Published As

Publication number Publication date
AU2013261918A1 (en) 2014-11-06
PH12014502512A1 (en) 2014-12-22
TW201350107A (zh) 2013-12-16
JP2015516455A (ja) 2015-06-11
HK1202808A1 (en) 2015-10-09
SG11201407536UA (en) 2014-12-30
WO2013171159A1 (en) 2013-11-21
CO7131352A2 (es) 2014-12-01
US20150111971A1 (en) 2015-04-23
IL235241A0 (en) 2014-12-31
CA2872210A1 (en) 2013-11-21
EA201492091A1 (ru) 2015-03-31
CL2014003081A1 (es) 2015-03-27
ZA201407655B (en) 2015-06-24
EP2849739A1 (en) 2015-03-25
EP2664327A1 (en) 2013-11-20
BR112014028280A2 (pt) 2019-09-24
KR20150013162A (ko) 2015-02-04
CN104302281A (zh) 2015-01-21
MX2014013851A (es) 2015-02-12

Similar Documents

Publication Publication Date Title
AR091039A1 (es) Composiciones farmaceuticas topicas que comprenden terbinafina, uso y metodo de tratamiento
CL2017000240A1 (es) Compuestos activos hacia bromodominios
CL2014002564A1 (es) Composiciones para tratamiento de agua que comprende un coagulante que contiene aluminio y un polisacarido no derivado natural, en donde la relacion entre el polisacarido y el coagulante es entre 1:10 hasta 1:100; y métodos de uso.
BR112015019657A2 (pt) composições tópicas e métodos de uso das mesmas
AR090456A1 (es) Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos
CL2017000287A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CR20150629A (es) Compuestos químicos
MX2016006641A (es) Composición novedosa y método de uso para controlar patógenos y prevenir enfermedades en semillas.
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
MX355174B (es) Formulaciones de uso topico de tetraciclina, preparaciones y usos de las mismas.
MX2015011520A (es) Composiciones antimicrobianas.
CL2013001589A1 (es) Uso de una emulsion que comprende 0,08% en peso o menos de aceite esencial antimicrobiano, goma acacia y agua para proporcionar un efecto antimicrobiano en una composicion acuosa; proceso para mejorar el efecto antimicrobiano de un aceite esencial antimicrobiano; y composicion acuosa que comprende una emulsion antimicrobiana.
DOP2015000170A (es) Compuestos químicos
CL2008001605A1 (es) Una formulacion de dosis intranasal que comprende asenapina o una sal farmaceuticamente aceptable y un portador liquido que contiene agua y un poliol, util para el tratamiento de la esquizofrenia.
AR089337A1 (es) Composiciones para el cuidado oral
PE20150353A1 (es) Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos
MX2019002396A (es) Composiciones oftalmicas.
DOP2016000007A (es) Pirazolpiridinas sustituidas
BR112016005589B8 (pt) Composição farmacêutica líquida, e, uso da mesma
CL2012003282A1 (es) Composicion farmaceutica topica que comprende, en base al peso total de la composicion a) 0,01 a 0,2% en peso de furoato de mometasona, b) 5 a 18% en peso de hexilenglicol, c) 20 a 40% en peso de agua y d) 25 a 70% en peso de una fase oleosa; y su uso para tratar o prevenir psoriasis, dermatitis atopica, entre otros.
EA201892563A1 (ru) Композиция для местного применения
HK1222337A1 (zh) 用於施加药物活性成分或化妆品活性成分的局部组合物和载体
AR090975A1 (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos

Legal Events

Date Code Title Description
FB Suspension of granting procedure